Literature DB >> 15017342

Clinical risk management in obstetrics.

Deborah A Holden1, Maureen Quin, Des P Holden.   

Abstract

PURPOSE OF REVIEW: Over recent years there has been a growing appreciation that a small but significant proportion of patients experience (sometimes serious) adverse events in the hands of health care workers. Although research in this area is very much in its infancy there has been an increasing move towards applying principles of risk management from industry to health care organizations. With the particularly disastrous and costly nature of adverse outcomes in obstetrics it is appropriate to review clinical risk management issues in maternity. RECENT
FINDINGS: This review explores the appropriateness of applying lessons learned in industry to maternity. The classification of errors into individual and latent, or organizational, is examined. Furthermore, the way in which these errors can be identified and subsequently analysed, with examples from maternity units in the UK and USA, is discussed. The importance of an educational and supportive environment, rather than a blame culture, for both reporting of incidents and learning from adverse outcomes is emphasized.
SUMMARY: Improvement in patient experience of health care rests not just with improved treatments, but also with a reduction in the adverse events which occur in health care institutions. The principles by which risk can be identified prospectively and retrospectively, and the mechanisms for both local risk management and regional/national reporting and learning are considered.

Entities:  

Mesh:

Year:  2004        PMID: 15017342     DOI: 10.1097/00001703-200404000-00007

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  1 in total

1.  Countering imbalanced datasets to improve adverse drug event predictive models in labor and delivery.

Authors:  L M Taft; R S Evans; C R Shyu; M J Egger; N Chawla; J A Mitchell; S N Thornton; B Bray; M Varner
Journal:  J Biomed Inform       Date:  2008-09-14       Impact factor: 6.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.